News | March 17, 2024
Sumitomo Pharma announces availability of ORGOVYX in Canada
The first and only oral androgen deprivation therapy treatment for men with advanced prostate cancer
The first and only oral androgen deprivation therapy treatment for men with advanced prostate cancer
Acquisition broadens oncology pipeline with a portfolio of novel T-cell engagers including HPN328 (MK-6070), an investigational delta-like ligand 3 (DLL3) targeting T-cell engager
With just few days of treatment, the patient started responding well and finally complete clinical resolution of infection was attained
Pfizer to discuss regulatory submission with FDA, potentially leading to eighth indication for ADCETRIS
It is the first autotaxin inhibitor to be investigated in cancer patients
Vision loss due to Glaucoma can be prevented if it is detected and treated early
Arun is currently working as Vice President (Strategy) in Solara leading Business finance & Strategy function
Acquisition of exclusive commercialization rights for European markets
Investigational cell therapy bemdaneprocel continues to be well tolerated with no major safety issues in all 12 participants in low and high dose cohorts through 18 months
Launch of Indian public health standards for Ayush healthcare facilities
Subscribe To Our Newsletter & Stay Updated
